olfactory receptor family 6 subfamily L member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR6L1P profile across patient tissues and cancer cell-line models. OR6L1P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, OR6L1P is differentially expressed in 1, with the highest sampling consensus in CHOL. Additionally, OR6L1P RNA expression shows 5,213 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, CHOL, and STAD as cancer lineages where OR6L1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR6L1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR6L1P survival associations across molecular data types. OR6L1P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR6L1P RNA expression–survival associations across cancer types. High OR6L1P expression shows unfavorable associations in ESCA, THCA, PAAD, ACC, BLCA and UCEC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ESCA as the clearest survival context for OR6L1P RNA expression.
This table summarizes OR6L1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for OR6L1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR6L1P shows lower tumor expression in CHOL. The CHOL box plot shows higher OR6L1P RNA expression in normal versus tumor tissue (log2 FC = −0.100, t-test p = .009).
This table shows molecular features associated with OR6L1P in patient tissues and cancer cell lines. In patient samples, OR6L1P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
